Congress Blocks Deep NIH Cuts and Restrictive Grant Overhaul, Preserving Research Lifelines

Researchers Dodge Major Funding Cliff—but New Barriers Loom

For NIH grant seekers, the drama isn’t over, but the existential threat has shifted. In a rare act of bipartisan resistance, Congress approved a $48.7 billion FY 2026 NIH budget—flat, but not slashed—thwarting the Trump administration’s bid to gut the agency by 40% and drastically rewrite the federal grant playbook. Institutions, principal investigators, and nonprofits narrowly avoided a loss that would have vaporized thousands of research projects and clinical trials. Yet, against this legislative lifeline, new executive maneuvers threaten to slow or shrink real support, leaving every applicant and current grantee in a tense, uncertain landscape.

How Congress Fought Back—and Why It Matters Now

This year’s budget cycle was anything but routine for the biomedical research community. Against the backdrop of political pressure for sweeping austerity, the Trump administration and OMB Director Russ Vought pushed for both a 40% cut in NIH funding and a multi-year grant policy that would have limited research opportunities by shrinking grant volumes and batch-issuing lump-sum awards. Many advocacy coalitions and lawmakers argued these moves would disrupt ongoing research, terminate clinical trials prematurely, and set back progress on cancer, Alzheimer's, and pandemic preparedness.

The final appropriations law, passed on February 3, 2026 (Senate committee summary), did the following:

• Restored $400 million in new funding for NIH versus FY 2025, a 0.9% increase to $48.7 billion
• Blocked the 40% cut and any new restrictive cap on indirect costs
• Limited new multi-year/grant consolidation policies by capping such schemes at last year’s levels and explicitly protecting existing cost structures
• Preserved flat or increased funding in related research agencies (NSF: down 3%, DOE Science: up 2%)
• Included $1.5 billion for ARPA-H (the newly-established biomedical projects accelerator)

For researchers, this preserves the possibility of new applications, renewals, and funded collaborations—especially for short-term, high-impact projects threatened by lump-sum or block-grant proposals.

Federal Pushback Isn’t Over: OMB Finds Loopholes and Delays Spending

The relief in academic and medical centers, however, is muted by new executive tactics. The Office of Management and Budget (OMB), led by the same architects of the failed reform, is using procedural levers to stymie the spending Congress authorized. OMB has thus far prevented the NIH from obligating much of the approved funds—effectively freezing appropriations through non-cooperation. This has already resulted in:

• Over $561 million in frozen research (including projects on cancer, heart disease, Alzheimer’s)
• More than 5,478 grants ended or not renewed last year, with hundreds of clinical trials canceled or defunded—impacting ~74,000 participants
• Termination or suspension of 383 active clinical trials, 118 in oncology

In addition, the NIH has rolled out the so-called “Unified Funding Strategy,” which does away with traditional paylines and makes the funding decision process more opaque and unpredictable. The result: many institutions have to retool how they strategize submissions, and new investigators face an even steeper climb.

Institutions Scramble to Interpret Policy—and Safeguard Their Portfolios

The bottom line for researchers and their sponsoring institutions is a fog of uncertainty. The administrative tug-of-war between Congress and the White House means:

• Universities and research hospitals must prepare for continued delays in awards, “parking” of funds, and last-minute administrative changes.
• Principal investigators (PIs) and teams should maintain backup plans for both personnel and project continuity; grant extensions, re-budgeting, or scope reductions may become the norm.
• Early-career and first-time applicants are at disproportionate risk, as established investigators often receive priority in a tighter funding environment and advocacy groups warn of declining award volumes.
• Nonprofits and patient advocacy groups that rely on NIH dollars may face service gaps or challenges launching new work, especially for high-need specialty or disease areas previously targeted for cuts.

While the legal guardrails passed by Congress should, in theory, secure the flow of funds, researchers shouldn’t assume business as usual. Stay in close contact with your NIH program officers, monitor for NOFO and policy updates, and seek clarity on indirect cost recovery or reporting rules, as these may quietly shift under new NIH strategies or OMB workarounds.

What’s Next: Oversight Battles, Legal Fights, and the 2027 Horizon

The White House’s resistance to congressional appropriations raises bigger issues about executive power and long-term research stability. Both major research associations and lawmakers are already hinting at oversight hearings and, potentially, lawsuits to force OMB compliance. Meanwhile, evolving policies could:

• Spur further legal action over improper grant terminations (especially if indirect cost caps or award freezes are quietly reintroduced)
• Lead to delayed or reduced NIH NOFO releases as agencies hesitate to open new competitions before knowing what’s really available
• Trigger intensified outreach and advocacy efforts as patient groups and affected researchers make their case to Congress for tighter statutory protections

For all stakeholders, closely watching the evolution of the OMB’s “Unified Funding Strategy”—including whether Congress moves to write even more restrictive appropriations language or confirm new NIH leadership—will be crucial. Those considering new applications should anticipate possible administrative hurdles, leave time for unexpected delays, and diversify funding streams if possible.

Every opening and closing of NIH’s funding spigot is a high-stakes event for the research enterprise; with administrative roadblocks still looming, grantseekers must keep their eyes glued to official communications and informed channels like Granted AI, which tracks these shifts as they happen.